BRANFORD, Conn., June 7 /PRNewswire/ -- The Institute for Diabetes Discovery, L.L.C. (IDD) has announced a novel class of compounds that has significantly reduced plasma glucose and insulin levels in models of insulin resistance and type 2 diabetes according to data presented at the 64th Scientific Session of the American Diabetes Association Annual Meeting in Orlando, Florida.
IDD's new compound IDD-3 is a member of a class of agents, which inhibits Protein Tyrosine Phosphatase 1b (PTP1b), a negative regulator in the insulin- signaling cascade. After a two-week treatment in the db/db model, IDD significantly reduced by 27% HbA1c, a key measure of glycemic control. By comparison, in the db/db model, the thiazolidinedione comparator pioglitazone lowered HbA1c by 14%. This activity was confirmed in a six-week study in the ob/ob model in which IDD-3 lowered HbA1c by 25% versus 13% for pioglitazone.
In a related study using a euglycemic clamp technique, also presented at the Orlando meeting, it was disclosed that IDD-3 acutely increased the glucose infusion rate by 28%, whereas thiazolidinediones have no acute effect on this parameter. The results indicate a marked improvement in insulin action after IDD-3 treatment,
To date, orally active compounds against PTP1b, a key PTPase, have been difficult for pharmaceutical companies to identify. IDD has synthesized and tested several series of orally active small-molecule PTP1b inhibitors. If efficacy and safety are confirmed by further studies, one of the compounds may be considered a therapeutic breakthrough for the treatment of diabetes in general and insulin resistance in particular.
In a statement describing additional benefits in IDD's program for treating insulin resistance, Nils Bergenhem, the organization's Vice President of Research, stated, "Insulin resistance is one of the key defects underlying the Metabolic Syndrome and diabetes. Although currently available insulin sensitizers are shown to improve metabolic conditions in type 2 diabetes, PTP1b inhibitors may improve metabolic activity without such known side effects of thiazolidinediones as fluid retention and weight/fat mass gain."
Commenting on the importance of IDD's new compounds, Professor Paul Zimmet, Chairman of the IDD Advisory Board and Director of the International Diabetes Institute in Melbourne, Australia said, "The diabetes epidemic is the largest in human history. The development of new compounds to address this international medical emergency is a vital initiative in attacking a disease that is crippling both the health and the healthcare budget of nations throughout the world."
The Institute for Diabetes Discovery, L.L.C. (IDD) is an affiliate of the Institutes for Pharmaceutical Discovery, L.L.C., a privately held pharmaceutical company located in Branford, Connecticut. IDD is a biopharmaceutical company specializing in the discovery and preclinical development of small-molecule drugs for the prevention and treatment of obesity, diabetes, and its complications.
The Institute for Diabetes Discovery, L.L.C.